AJMC October 3, 2022
One of the first parts of the landmark Inflation Reduction Act took effect Monday; it boosts the add-on payment for qualifying biosimilars whose average sales price is not more than the price of its reference product from 6% of the reference product’s ASP to 8% for 5 years.
Temporary Medicare Part B payment changes went into effect Monday for the implementation of certain biosimilars, HHS said.
It is one of the first provisions of the Inflation Reduction Act (IRA) to start, and it is part of a strategy to increase access to lower-cost biosimilars, as well as to encourage competition between biosimilars and originator biologics, in the hopes of lowering overall drug costs and creatting savings for beneficiaries and the...
Today's Sponsors
Today's Sponsor